logo

For the Inventor, By the Inventor

Kelkheim, Germany

Dieter Bormann

This inventor holds 18 USPTO granted patents. Top assignees: Hoechst Aktiengesellschaft, Roussel Uclaf. Active years: 1976-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dieter Bormann. Retrieved from https://idiyas.com/inventor/dieter-bormann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 248(Granted Patents)


Location History:

  • Kelkheim, Taunus, DE (1976 - 1978)
  • Kelkhein, Taunus, DE (1978)
  • Kelkhein, DE (1979)
  • Kelkheim, DE (1979 - 1998)

Company Filing History:

goldMedal17 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents
silverMedal1 out of 854 
 
Roussel Uclaf
 patents

Years Active: 1976-1998

Loading Chart...
18 patents (USPTO):Explore Patents
1. 5710146 - Cephem derivatives and processes for their manufacture (1998-01-20),
2. 5089490 - Cephem derivatives (1992-02-18),
3. 4758556 - Cephem derivatives (1988-07-19),
4. 4492710 - Substituted pyrrolidinyl-benzoic acid derivatives and a process for (1985-01-08),
5. 4393072 - Thienylbenzoic acid derivatives (1983-07-12),
6. 4282220 - Cephem derivatives (1981-08-04),
7. 4278793 - Cephem derivative (1981-07-14),
8. 4224371 - Sodium (1980-09-23),
9. 4201779 - 7[(2-Amino-thiazol-4-yl)glyoxylamido]-cephem derivatives and processes (1980-05-06),
10. 4172142 - Process for preparing pyrrolo-benzoic acid derivatives (1979-10-23),
11. 4161531 - Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a (1979-07-17),
12. 4118397 - Derivatives of 5-aminobenzoic acid having a heterocyclic substituent in (1978-10-03),
13. 4111953 - Derivatives of 5-aminobenzoic acid having a heterocyclic substituent in (1978-09-05),
14. 4093735 - 5-Sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent (1978-06-06),
15. 4016159 - Acylamino-cephem-carboxylic acids containing an amidino or guanidino (1977-04-05),

Title: **Dieter Bormann: Innovator in Pharmaceutical Chemistry**

Introduction

Dieter Bormann is a prominent inventor based in Kelkheim, Germany, with a remarkable portfolio of 18 patents. His innovative contributions in the field of pharmaceutical chemistry have made significant advancements in the treatment of bacterial infections.

Latest Patents

Among his latest work, Bormann has developed patents related to cephem derivatives and processes for their manufacture. These cephem derivatives, defined by the general formula, exhibit the R2O group in the syn-position and are integral to the development of pharmaceutical formulations that are effective against bacterial infections. His focus on these compounds illustrates his commitment to enhancing medical science and improving patient outcomes.

Career Highlights

Throughout his career, Bormann has worked with renowned companies, including Hoechst Aktiengesellschaft and Roussel Uclaf. His experiences in these influential organizations have provided him with the platform to innovate and advance his research in pharmaceutical chemistry.

Collaborations

Dieter Bormann has collaborated with notable colleagues in his field, including Wulf Merkel and Elmar Schrinner. These partnerships have been essential in fostering a collaborative environment that promotes groundbreaking inventions and advancements in medicinal research.

Conclusion

In summary, Dieter Bormann stands out as a leading inventor in the pharmaceutical industry. His dedication to creating effective treatments through innovative cephem derivatives has positioned him as a key contributor to medical advancements in combating bacterial infections. His work continues to inspire future innovations in the field of chemistry and pharmaceuticals.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…